Press release content from PR Newswire. The AP news staff was not involved in its creation.

Click to copy

IRVINE, Calif., Oct. 15, 2019 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today that the Companys ROOT of SKIN line of rejuvenating skincare products sold out in its tenth appearance on the Japanese home shopping channel QVC Japan.

ROOT of SKIN is AIVITAs proprietary skincare line for skin rejuvenation, made possible through the same proprietary knowledge and expertise used to develop its cutting-edge stem cell therapies. SourceCode Technology, the proprietary actives complex in ROOT of SKIN, contains the complete set of factors and supporting biological components present in young, healthy skin.

AIVITA Biomedical uses 100% of the proceeds from ROOT of SKIN sales to support the treatment of women with ovarian cancer.

Outstanding market traction, a product that truly works, and a benevolent use of proceeds, said Hans Keirstead, AIVITAs Chief Executive Officer. This sets the stage for global expansion of our ROOT of SKIN product line.

About ROOT OF SKIN

ROOT of SKIN is a rejuvenating line of skincare products fueled by an unrelenting pursuit for advancements in life-changing and life-saving treatments. Harnessing breakthroughs in stem cell therapy, AIVITA Biomedical developed a technology that does more than just boost regeneration. The patented actives complex SourceCode Technology renews, repairs and protects, just as your skin did at its youngest and healthiest stage. Rich with every biological component healthy skin needs for development, and free of any unnecessary ingredients. All proceeds support treatment of women with ovarian cancer.

About AIVITA Biomedical

AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products.

View original content to download multimedia: http://www.prnewswire.com/news-releases/root-of-skin-skincare-products-sell-out-in-tenth-consecutive-appearance-on-qvc-japan-300938926.html

SOURCE AIVITA Biomedical, Inc.

Visit link:
ROOT OF SKIN Skincare Products Sell Out in Tenth Consecutive Appearance on QVC Japan - Associated Press

Mogrify Ltd (Mogrify), a UK company aiming to transform the development of life-saving cell therapies, recently announced the initial close of its Series A funding. The Company raised $16M USD in this round, bringing the total investment to over $20M USD to date. The funding will support internal cell therapy programs, and the development and out-license of novel IP relating to cell conversions of broad therapeutic interest. Mogrify is also actively recruiting, and will increase headcount to 60 scientific, operational and commercial staff located at its state-of-the-art facility on Cambridge Science Park.

The funding round was led by existing investor Ahren Innovation Capital (Ahren), an investment fund co-founded by leading UK scientific entrepreneurs, supporting transformational companies at the cutting edge of deep science and deep tech. Parkwalk, the largest EIS growth fund manager, backing businesses with IP-protected innovations creating solutions to real-world challenges, 24Haymarket, an early investor in Mogrify and a prolific early-stage investment syndicate in deep technology and the life sciences, and the University of Bristol Enterprise Fund III, also contributed to the fundraise.

Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state. The Company is deploying this platform to develop novel cell therapies addressing musculoskeletal, auto-immune, cancer immunotherapy, ocular and respiratory diseases as well as generating a broad IP position relating to cell conversions that exhibit safety, efficacy and scalable manufacturing profiles suitable for development as cell therapies.

Mogrify is commercializing its technology platform via a model that includes development and out-license of internally developed cell therapy assets, development and license of novel cell conversion IP, and the formation of joint-ventures to exploit the platform and/or novel cell conversion IP in non-core areas.

Mogrify launched in February 2019, announcing $3.7M USD seed funding from Ahren, 24Haymarket and Dr. Darrin M. Disley, OBE and went on to secure grants from Innovate UK and SBRI Healthcare.

Mogrify also strengthened its management and scientific teams and relocated a 20-strong workforce to its new headquarters at TusParks Cambridge Bio-Innovation Centre on Cambridge Science Park in May. It has now begun recruiting up to 40 additional commercial, operational and scientific roles to support its expanding pipeline of internal programs, as well as supporting numerous biotech and pharma collaborators in developing novel IP to underpin existing and new cell therapy programs.

Dr. Darrin M. Disley, OBE, CEO, Mogrify, said: Following the recent announcement of Dr. Jane Osbourn, OBE, as Chair of Mogrify, I am delighted we have been able to make an initial close of this fundraising round, with the backing of both existing and new investors. Due to the significant interest, we have been able to secure this growth-funding without engaging in a protracted and distracting fund-raising process. Having now raised over $20M, we can focus on delivery of our business strategy with the support of an aligned investor group. We will continue to engage with high-caliber investors with computational biology and cell therapy domain expertise as part of our on-going investor relations and capital markets strategy.

Alice Newcombe-Ellis, Founder and Managing Partner, Ahren Innovation Capital, said: Mogrifys technology is well positioned to disrupt the global cell therapy market. The Company has grown rapidly since February, appointing a world-class management team and delivering strongly against its business plans. We look forward to supporting Mogrify as it continues to go from strength to strength.

Alastair Kilgour, Chief Investment Officer, Parkwalk, said: We are delighted to be supporting the team at Mogrify, many of whom have been involved successfully with companies we have previously invested in, in this investment round. The science and technology base Mogrify are building is truly unique and disruptive. If successful, the positive effect on patient outcomes across a wide range of diseases will be staggering.

Alice Newcombe-Ellis, Founder and Managing Partner of Ahren, and Alastair Kilgour, Chief Investment Officer, Parkwalk, both join Mogrifys board of directors along with Dr. Karin Schmitt, the Companys Chief Business Officer.

For more information, visit https://mogrify.co.uk/investors/

About MogrifyMogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.

The platform takes a systematic big-data approach to identify, from next-generation sequencing and gene-regulatory networks, the transcription factors (in vitro) or small molecules (in vivo), needed to convert a cell. By bypassing the stem cell-stage of cell transformation, Mogrify simultaneously addresses challenges associated with efficacy, safety and scalability.

Mogrify is deploying this platform to develop novel cell therapies addressing musculoskeletal, auto-immune, cancer immunotherapy, ocular and respiratory diseases as well as generating a broad IP position relating to cell conversions that exhibit safety, efficacy and scalable manufacturing profiles suitable for development as cell therapies.

Uniquely positioned to address a cell therapy market estimated to be $35B USD by 2023, Mogrify is commercializing its technology via IP licensing, product development, and drug development. Based in Cambridge, UK, the Company has raised over $20M USD funding from Ahren Innovation Capital, Parkwalk, 24Haymarket, Dr. Darrin M. Disley, OBE and the University of Bristol Enterprise Fund III. For more information, visit http://www.mogrify.co.uk

About Ahren Innovation CapitalAhren LP is an investment fund that supports transformational companies at the cutting edge of deep science and deep tech. The technologies of its Founding Partners are today valued more than $100B combined.

A group of highly diverse, creative and original thinkers leading their domains, Ahren believes in taking considered risk that will deliver superior rewards capturing a generational opportunity to provide smart capital to deep technology pioneers.

With a philosophy espousing the importance of relationships and trust, Ahren provides long-term capital and support to exceptional founders and teams, empowering them to achieve the unimaginable.

Ahren Innovation Capital was founded by Alice Newcombe-Ellis, together with Science Partners Sir Shankar Balasubramanian, Professor John Daugman, Professor Zoubin Ghahramani, Professor Steve Jackson, Professor Andy Parker, Sir Venki Ramakrishnan, Lord Martin Rees and Sir Gregory Winter. For more information, visit http://www.ahreninnovationcapital.com

About ParkwalkParkwalk is the largest growth EIS fund manager, backing world-changing technologies emerging from the UKs leading universities and research institutions. With 250M of assets under management, it has invested in over 100 companies across its flagship Parkwalk Opportunities EIS Fund as well as the award-winning enterprise and innovation funds Parkwalk manages for the Universities of Cambridge, Oxford and Bristol.

Parkwalk invests in businesses creating solutions to real-world challenges, with IP-protected innovations, across a range of sectors including life sciences, AI, quantum computing, advanced materials, genomics, cleantech, future of mobility, MedTech and big data.

For more information, visit http://parkwalkadvisors.com

About 24Haymarket24Haymarket is a premium deal-by-deal investment platform focused on high-growth businesses, investing up to 5M in any company. 24Haymarkets Investor Network includes several highly experienced private equity and venture capital investors, seasoned entrepreneurs and senior operators. We invest our own capital in direct alignment with entrepreneurs and typically seek Board representation to actively support their growth agenda. Since its inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses. For more information, visit http://www.24haymarket.com

The University of Bristol Enterprise Fund III (Managed By Parkwalk)The University of Bristol Enterprise Fund is an early stage investment fund backing scientific and technological companies spun out of the University of Bristol or being supported by the Universitys SETsquared incubator. For more information, visit http://parkwalkadvisors.com/fund/university-of-bristol-enterprise-fund.

Read more from the original source:
Mogrify Raises Additional $16M To Advance Its Mission To Transform The Development Of Life-Saving Cell Therapies - Clinical Leader

In AML, the role of ecotropic virus integration site-1 (EVI1) expression is debated. To date, results of studies have been mixed with only some studies demonstrating EVI1 expression related to poorer survival. In a meta-analysis published in the Annals of Hematology, researchers set out to uncover the predictive capability of this marker.

As a malignant disorder in hematology usually with a poor prognosis, AML needs an accurate prediction of prognosis to indicate protocoling the appropriate therapy regimens for patients hoping for survival improvement, wrote authors, led by Xia Wu, Department of Hematology, West China Hospital, Sichuan University, Sichuan Province. Molecular markers increasingly play an utmost significant role in the diagnosis and risk stratification of AML.

In the current meta-analysis, Wu et al. mined 11 studies for 4767 AML patients with intermediate cytogenetic risk (ICR), according to National Comprehensive Cancer Network (NCCN), International System for Human Cytogenetic Nomenclature (ISCN), or European leukemia network (ELN) guidance. The findings indicated that EVI1 expression negatively impacted OS (HR = 1.73, 95%CI 1.432.11) and event=free survival or EFS (HR = 1.17, 95%CI 1.051.31). Furthermore, EVI1 was a negative predictor of prognosis in patients with normal cytogenetics (NC) and younger patients (< 60 years).

Importantly, the investigators noted that due to location, altered EVI1 most often accompanies 3q26 rearrangements. However, it remains to be elucidated whether increased EVI1 expression is related to AML outcomes in those without 3q mutations. On a related note, higher levels of EVI1 may affect AML subgroups differently, which, according to the authors, is of utmost significance for clinical physicians.

In other findings, EVI1H expression was rarely found with NPM1, FLT3-ITD and DNMT3A mutations. Wu et al point to these mutations and mutations as avenues of further research.EVI1 is a transcription factor on chromosome 3. It was first discovered two decades ago in murine models. It has stem cell specific expression patterns and mediates growth of hematopoietic stem cells, and plays a role in AML, myelodysplastic syndrome (MDS), and CML.

The investigators suggested that the findings of the current study could assist clinicians with risk stratification and treatment decisionsespecially because most patients are NC.

EVI1, which also goes by MECOM, encodes a 145 kDa-unique zinc finger that attaches with DNA. This transcription factor is hypothesized to interfere with granulocyte and erythroid cell differentiation, as well as promotion of megakaryocyte breakdown, to aid with the differentiation and proliferation of hematopoetic stem cells.Several drug targets for EVI1 have been suggested such those involved in leukemogenesis and stem cell maintenance. Examples include the transcription factor Pre-B Cell leukemia Homeobox 1 (PBX1) and Phosphatase and Tensin Homolog (PTEN), which is a tumor suppressor gene. However, none of these targets have proven related to EVI1-deregulated AML.

Per the authors the current study had several limitations. First, most studies in the meta-analysis were observational and not randomized-controlled trials. Second, the sample contained cases of therapy-related AML and secondary AML, which have a worse prognosis and could thus confound results. Third, limited OS data precluded the ability to study AML patients without 3q alterations. Fourth, the studies were highly heterogeneous in a clinical sense.

Reference

Wu X et al. Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis. Annals of Hematology. 2019 Sep 3. doi: 10.1007/s00277-019-03774-z.

Originally posted here:
The Prognostic Importance of EVI1 Expression - Cancer Network

NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (Rocket), a leading U.S.-based multi-platform gene therapy company, today announces data presentations at the upcoming European Society of Cell and Gene Therapy (ESGCT) 27th Annual Congress taking place October 2225, 2019, in Barcelona, Spain. Presentations at this years meeting include four oral presentations and one poster presentation related to Rockets lentiviral pipeline programs for Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD), Pyruvate Kinase Deficiency (PKD), and Infantile Malignant Osteopetrosis (IMO).

Details for Rockets oral and poster presentations are as follows:Title: Towards Haematopoietic Stem Cell-Targeted Gene Therapy of Infantile Malignant OsteopetrosisSession Title: Skeletal Muscle & Bone Gene TherapySession Date: Wednesday, October 23, 2019Session Time: 5:30 PM 7:30 PM CESTRoom: 116-117

Title: Gene Therapy for Patients with Fanconi AnaemiaSession Title: Gene Therapy Clinical Trials IISession Date: Thursday, October 24, 2019Session Time: 8:30 AM - 10:30 AM CESTRoom: 113-117

Title: First Steps of a Lentiviral Gene Therapy Clinical Trial for Pyruvate Kinase DeficiencySession Title: Blood DiseasesSession Date: Thursday, October 24, 2019Session Time: 2:45 PM - 4:45 PM CESTRoom: 211

Title: Broad Applicability of NHEJ-Mediated Gene Editing to Correct Mutations in a Variety of Fanconi Anaemia GenesSession Title: New Approaches in Gene EditingSession Date: Friday, October 25, 2019Session Time: 9:00 AM - 11:00 AM CESTRoom: 113-115

Title: Stable Transduction of Long-Term HSCs Under Optimized GMP-Conditions for the Gene Therapy of LAD-I PatientsSession Title: Poster Session IISession Date: Thursday, October 24, 2019Session Time: 1:15 PM - 2:45 PM CESTPoster Number: P228

Full results from the ESGCT presentations will be available online at the conclusion of the presentation: https://www.rocketpharma.com/esgct-presentations/

About Rocket Pharmaceuticals, Inc.Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rockets multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket's first two clinical programs using LVV-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, and Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal. Rockets first clinical program using AAV-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. Rockets pre-clinical pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD) and Infantile Malignant Osteopetrosis (IMO). For more information about Rocket, please visit http://www.rocketpharma.com.

Rocket Cautionary Statement Regarding Forward-Looking StatementsVarious statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantile Malignant Osteopetrosis (IMO) and Danon disease, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's ability to successfully demonstrate the efficacy and safety of such products and pre-clinical studies and clinical trials, its gene therapy programs, the pre-clinical and clinical results for its product candidates, which may not support further development and marketing approval, the potential advantages of Rocket's product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket's and its licensors ability to obtain, maintain and protect its and their respective intellectual property, the timing, cost or other aspects of a potential commercial launch of Rocket's product candidates, Rocket's ability to manage operating expenses, Rocket's ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket's Annual Report on Form 10-K for the year ended December 31, 2018. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

See the original post here:
Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress - Business Wire

Oct 15, 2019

The Equine Medical Research Fund was created in 2014 to provide consistent funding for equine medical research, which has historically been underfunded. A $1.00 starter fee was added to each USEA recognized event entry beginning in 2014, and at years end a majority of those dollars were distributed through the Morris Animal Foundation, which assists the USEA with selecting studies to fund, monitoring the funds, and reporting on progress. Morris has decades of experience in reviewing grant applications from universities and research institutions and has a team of veterinarians who spend thousands of volunteer hours assessing which studies are most likely to impact horse welfare. Ultimately, a committee from the USEA comprised of riders and veterinarians will determine which studies the USEA dollars will target.

This years committee recommendation is a bit different as the committee is recommending spreading funds among three entities - the Stephen Teichman Farrier study, a Grayson Jockey Club Research Foundation study, and two Morris Animal Foundation Studies.

Through these partnerships, the USEA is helping to address the major problem of equine research underfunding while maintaining control over how member dollars are distributed. Although the committee is always interested in recommending studies that concern general horse welfare, this year we took a closer look at recommending studies that were geared to solving issues that concern performance horses. The goal of our selection philosophy is to provide USEA positive PR through funding a variety of institutions and studies that show our support for horse care, welfare, and rehabilitation.

In 2017, $46,900 dollars were distributed between five different studies on different topics pertaining to equine health, from improving regenerative therapies to studying gaps in the equine genome related to tendon health.

In 2018, $44,858 dollars were distributed between four different studies on a variety of topics including insulin's relation to laminitis, stem cell therapies, equine asthma, and joint infections.

At the USEA Board of Governors meeting in August, the Equine Medical Research Committee recommended the funding of four studies using the $39,581 collected in 2018 and the Board approved their recommendation. Below are additional details about the four selected studies.

Non-Invasive Evaluation of Host-Microbiota Interactions Canaan Whitfield-Cargile, Texas A&M

Summary: This study aims to develop a non-invasive platform to serve as a diagnostic test for gastrointestinal inflammation prior to severe disease and to reveal how bacteria in the gut influence horse health.

Description: One of the most important and common classes of diseases affecting horses are gastrointestinal (GI) diseases including colic and colitis. Despite tremendous research efforts to both diagnose and prevent these diseases, they remain very common and frequently are not diagnosed until severe disease is present. One area that is gaining recognition as an important player in equine GI health and disease is GI bacteria or the microbiota. The microbiota consists of all of the bacteria and other microorganisms in the GI tract. Alterations in the amounts and types organisms that make up the microbiota have been linked to both GI and non-GI diseases of horses including colic, colitis, laminitis, and obesity. These findings are part of the reason why there are a vast array of prebiotics, probiotics, and other products on the market that claim to influence the GI microbiota. Unfortunately, there is minimal evidence to support the efficacy of these products and a lack of understanding of how these products work. A major contributor to the lack of evidence and understanding of these products is related to an inability to monitor the health and function of the equine GI tract. It is clear when severe disease is present but currently impossible to monitor subtle changes. Similarly, while we can easily diagnose severe inflammation and microbiota changes during disease, we cannot capture the changes that occurred prior to clinical disease. These limitations result in capturing results of GI injury and disease but not causes. Consequently, there is great need for improved understanding of the causes of disease and early identification of horses at-risk of developing GI disease. In the absence of such knowledge, effective intervention strategies to reduce GI and GI-related health risks will remain elusive.

Horses and other animals naturally shed cells lining the GI tract on a daily basis. People, in fact, shed up to 1/3 of the cells lining their GI tract daily. We have developed a technique for examining the gene expression profile of these cells to monitor the health and function of the GI tract from fecal samples. We have shown that this approach offers a promising means to non-invasively examine the response of the GI intestinal tract to injury. Further, we have convincing preliminary data demonstrating that the gene expression profile arising from these cells mirrors the gene expression profile of the tissues within the GI tract of the horse and provides a global view of the health and function of the GI tract. This approach offers a highly attractive, non-invasive means of monitoring GI responsiveness to disease and interventions. Thus, our long-term goals are to 1) develop inexpensive, non-invasive diagnostic tests in order to document GI inflammation prior to the onset of severe disease in horses; and, 2) by examining host and microbiota data simultaneously we aim to elucidate the mechanisms of host-microbiota interactions in the context of health and disease. Ultimately, we aim to use this approach to identify specific pathway by which the host and microbiota interact so that this critically important interaction can be targeted therapeutically.

In order to achieve our goals, we will utilize a reversible model of GI inflammation with which we have extensive experience. We will induce GI inflammation with the non-steroidal anti-inflammatory drug (NSAID) phenylbutazone and noninvasively interrogate the response and response of the microbiota. Importantly, we will collect samples sequentially both before and after induction of inflammation in order to gain predictive and diagnostic information about GI inflammation in horses. This approach will have broad application to many equine intestinal disorders and will provide the much needed mechanistic insight into disease development and progression, thereby enabling us to develop effective prevention and treatment strategies for equine GI disease.

The total cost of this study is $46,756 in 2019 and $45,814 in 2020. The EMRC recommends $12,000 for funding this study.

Paraoxonase-1 Activity as a Marker for Diagnosis of Equine Metabolic Syndrome Gabriele Rossi, DVM, Ph.D., DECVCP Murdoch University

Summary: Researchers will investigate a new laboratory test to improve diagnosis of equine metabolic syndrome, a metabolic and hormonal disorder in horses.

Description: Equine metabolic syndrome (EMS) is characterized by abnormal insulin regulation, obesity, and susceptibility to laminitis. EMS is challenging to diagnose since laboratory tests fail to distinguish EMS from other common equine diseases. Human metabolic syndrome (HMS) shares similar laboratory features to EMS and a new serum biomarker has been proposed in human medicine to improve the diagnosis of HMS. Researchers will investigate if this new HMS test also can provide an accurate diagnosis for horses with EMS. A new efficient and cost-effective EMS test will help veterinarians better diagnose and manage this complex disease in horses.

The total cost of this study is $9,355. The EMRC recommends $9,355 to fund this study.

Cell-mediated immunogenicity and MHC expression regulation of TGF-beta2-treated mesenchymal stem cells for improved clinical use in the horse. Lauren V Schnabel, DVM, Ph.D., DACVS, DACVSMR North Carolina State University

Summary: Researchers will manipulate the expression of immune markers on stem cells to develop safer and more effective therapies for horses with musculoskeletal injuries.

Description: Stem cell therapies have the potential to improve the outcome of potentially severe and life-ending musculoskeletal injuries in horses. However, sometimes the recipients immune system will destroy transplanted stem cells if the immune system perceives the introduced cells as foreign. To improve stem cell treatment success, researchers will examine if a novel cell culture treatment can be used to prevent the immune system from destroying donor stem cells. This study will help researchers better understand the cellular regulation of the molecules that initiate immune responses and advance the development of convenient and effective off-the-shelf stem cell therapy.

The total cost of this study is $131,479. The EMRC recommends $12,000 to fund this study. This is the second year that we are recommending funding this 3 year study.

Stephen Teichman Study

The goal is to determine the effects of front shoe surface modifications in the sport horse on the duration of breakover. We discussed and agreed to support this study during the May BOG conference call providing the publishing and professional fees were researched and found to be reasonable, which they were.

The total cost of this study is $9,640. The EMRC recommends USEA to provide $4,820 and an additional $4,820 is to be contributed by other donors.

This brings the total recommended research total to $38,175, leaving $1,406 of use at another time.

For an update on studies previously selected for funding by the USEA Equine Medical Research Committee, click here. To learn more about how the Equine Medical Research Fund got started, click here. For additional information about the Fund, click here.

Link:
Equine Medical Research Funding Receives USEA Board of Governors - United States Eventing Association

Oct. 16, 2019 08:12 UTC

TOKYO--(BUSINESS WIRE)-- Utilizing the capability of ones own immune system to tackle cancer, an out-of-the box idea was the brain child of Dr. Steven Rosenberg almost three decades ago. His initiative which paved way for a new chapter in oncology, inspired many young scientists and clinicians in the NCRM NICHE 2019 held in Tokyo, Japan, as his acceptance speech in the Edogawa NICHE Prize ceremony was videocast.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191016005321/en/

Winners of XIV Fujio Cup Quiz receiving the trophy from Dr. Masahiro Katoh, Chairman Edogawa Hospital (3rd from Rt) with Prof. Jurgen Hescheler (2nd from Rt) and Dr. Shojiro Katoh (2nd from Lt) (Photo: Business Wire)

NCRM NICHE, an active knowledge gaining academic event since 2006 in which young scholars from all over the world compete for the Fujio Cup Quiz (FCQ) in regenerative medicine is evolving to be an open innovation platform according to Dr. Shojiro Katoh, Chairperson of Edogawa Evolutionary Lab of Science (www.eels.tokyo), a co-host. He added that the FCQ motivated his team research on 16 different themes in Regenerative Medicine in various clinical specialties, among which two have completed clinical pilot studies with successful outcome viz., corneal endothelial regeneration and urethral stricture repair.

The XIV edition of FCQ contest that witnessed teams from Malaysia, Indonesia and India in the finals, was won by Reshma Romanas and Aayurshi Agrahari of Kasturba Medical College, India. Alumni of the FCQ are now eligible to nominate the awardees for Edogawa NICHE Prize which was established in 2018 to honour scientists or clinicians who develop novel solutions in healthcare, based on inter-disciplinary interactions. Dr. Steven A. Rosenberg, Chief of surgery, National Cancer Institute, NIH, USA is the recipient of the award in 2019. The award portrays such accomplished role models to the FCQ Elites according to the organizers who have instituted Joyce & James Till Travel Grant with a generous grant by Prof James Till, that supports travel of yesteryears FCQ Elites, who are now accomplished researchers in their own rights to meet and inspire the FCQ Elites of today, thus bringing together science and generations across nations.

NCRM NICHE is supported by a consortium with EELS as knowledge partners and JBM Inc., as industry partners based in Tokyo which has set up a hybrid cell culture cum biomaterials lab for taking forward the cell therapy and tissue engineering innovations to bed side, with future plans to propagate them globally through networking with like-minded academic and industry partners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191016005321/en/

Original post:
Accomplishments of Dr. Steven Rosenberg in Cancer Immunotherapy Inspire Young Researchers in Japan & XIV Fujio Cup Quiz on Stem Cells Is Won by...

The report on Global Animal Stem Cell Therapy Market added by CMR depicts the current & future growth trends of this business besides outlining details pertaining to the myriad geographies that are a part of the regional landscape of Animal Stem Cell Therapy Market. The report further elucidates intricate details regarding the supply and demand analysis, Market share, growth statistics and contributions by leading industry players of Animal Stem Cell Therapy Market.

These Animal Stem Cell Therapy industry trends for short-term, mid-term and long-term during the anticipate phase. Further, the report also covers key players profiling with comprehensive Animal Stem Cell Therapy SWOT analysis, financial facts and key developments of products/service from the past three years.

Get Exclusive Sample PDF Copy of this Report @https://www.crystalmarketresearch.com/report-sample/HC084561

Animal Stem Cell Therapy Market, By Key Players

Check Exclusive Discount on this report @https://www.crystalmarketresearch.com/check-discount/HC084561

Inquiry More to get further questions resolved: https://www.crystalmarketresearch.com/send-an-enquiry/HC084561

Contacts Us:

Judy | 304 South Jones Blvd, Suite 1896

Las Vegas NV 89107

United States

E-mail: sales@crystalmarketresearch.com | Ph: +1-888-213-4282

See the original post here:
Exclusive Growth Report on Animal Stem Cell Therapy Market 2019 Increasing Demand with Leading Key Players: J-ARM,U.S. Stem Cell,Celavet Inc. - Pledge...

The report sheds light on the highly lucrative Global Animal Stem Cell Therapy Market and its diversifying nature. The report provides a detailed analysis of the market segmentation, size, and share; market dynamics such as the growth drivers, restraints, challenges, and opportunities; service providers, investors, stakeholders, and key market players. In addition, the report highlights the threat factors that the market will likely encounter over the forecast period. The report provides detailed profile assessments and multi-scenario revenue projections for the most promising industry participants. The Global Animal Stem Cell Therapy Industry report focuses on the latest trends in the global and regional spaces on all the significant components, including the capacity, cost, price, technology, supplies, production, profit, and competition.

The report also includes a detailed assessment on the key strategies and approaches implemented by the leading industry players and also provides the market share forecasts. The report presents some illustrations and presentations with regards to the market, which includes graphs, tables and pie charts, representing the percentage split of the strategies adopted by the key players in the global market. The product launches are regarded as one of the key strategies adopted by the leading market competitors in the Global Animal Stem Cell Therapy Market so as to present novel and innovative products in different business segments.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (M USD), market share and growth rate of Animal Stem Cell Therapy in these regions, from 2012 to 2023 (forecast), covering

Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-animal-stem-cell-therapy-2025-90

Global Animal Stem Cell Therapy market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Animal Stem Cell Therapy for each application, including

If you have any special requirements, please let us know and we will offer you the report as you want.

Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-animal-stem-cell-therapy-2025-90

Table of content

1 Report Overview1.1 Definition and Specification1.2 Report Overview1.2.1 Manufacturers Overview1.2.2 Regions Overview1.2.3 Type Overview1.2.4 Application Overview1.3 Industrial Chain1.3.1 Animal Stem Cell Therapy Overall Industrial Chain1.3.2 Upstream1.3.3 Downstream1.4 Industry Situation1.4.1 Industrial Policy1.4.2 Product Preference1.4.3 Economic/Political Environment1.5 SWOT Analysis

2 Product Type Market2.1 World Product Type Market Performance and Trend2.1.1 World Market Performance2.1.2 Different Type of Market Performance2.2 North America Product Type Market Performance and Trend2.2.1 North America Market Performance2.2.2 Different Type of Market Performance2.3 Europe Product Type Market Performance and Trend2.3.1 Europe Market Performance2.3.2 Different Type of Market Performance2.4 Asia-Pacific Product Type Market Performance and Trend2.4.1 Asia-Pacific Market Performance2.4.2 Different Type of Market Performance2.5 South America Product Type Market Performance and Trend2.5.1 South America Market Performance2.5.2 Different Type of Market Performance

CONTACT US:276 5th Avenue, New York, NY 10001,United StatesInternational: (+1) 646 781 7170 / +91 8087042414Email: help@grandresearchstore.com

Follow Us On linkedin:- https://www.linkedin.com/company/grand-research-store/

Follow this link:
Animal Stem Cell Therapy Market by Manufacturers, Regions, Type and Application, Forecast to 2025 - Market Insights

Geographically, global Animal Stem Cell Therapy market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-animal-stem-cell-therapy-2019-245

On the basis of product, we research the production, revenue, price, market share and growth rate, primarily split into

For the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Animal Stem Cell Therapy for each application, including

Production, consumption, revenue, market share and growth rate are the key targets for Animal Stem Cell Therapy from 2013 to 2024 (forecast) in these regions

Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-animal-stem-cell-therapy-2019-245

Table of content

1 Report Overview1.1 Definition1.2 Manufacturers and Regions Overview1.2.1 Manufacturers Overview1.2.2 Regions Overview1.3 Type Overview

2 Global Animal Stem Cell Therapy Market Assesment by Types2.1 Overall Market Performance2.1.1 Product Type Market Performance (Volume)2.1.2 Product Type Market Performance (Value)2.2 China Animal Stem Cell Therapy Market Performance2.3 USA Animal Stem Cell Therapy Market Performance

Key Que Answered in this report:

What is our report offers:

Strategic suggestions and proposals for the beginners to understandAssessments of the market share from different countries and regions were conductedTop key market players, market share analysis included.The market observations such as constraints, drivers, threats, opportunities, investment opportunities, challenges, and recommendations are added.The competitive landscaping mappings of the ongoing trends are discussed.Based on the market estimations, the strategic recommendations are made in the business segments

CONTACT US:276 5th Avenue, New York, NY 10001, United StatesInternational: (+1) 646 781 7170 / +91 8087042414Email: help@grandresearchstore.com

Follow Us On LinkedIn:- https://www.linkedin.com/company/grand-research-store/

Read the original:
Animal Stem Cell Therapy Market Research Report 2019 by Manufacturers, Regions, Types and Applications - Market Insights